B.K. Pharma SRL
0.7 FTEThe score of B.K. Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +145 % Total assets -8 % Headcount (avg FTE) -30 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
B.K. Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 26,588 € | ||||
| Equity | 192,565 € | ||||
| Cash | 78,043 € | ||||
| EBITDA | 60,707 € | ||||
| Total assets | 421,476 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 Aug 2026
- Year ended 31 Dec 2024filed on 23 Jul 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 28 Jul 2023
- Year ended 31 Dec 2021filed on 30 Sep 2022
B.K. Pharma's financial analysis
- Solvency45.7%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of B.K. Pharma
B.K. Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0834.173.472
- VAT number
- BE0834173472
- Peppol
- Registered · 0208:0834173472 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 01 Mar 2011
- Registered office
- 1070 Anderlecht
- Size
- Micro · 0.7 FTE
- Latest accounts
- 2025 · filed on 28 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
B.K. Pharma (SRL) has been based in Anderlecht since 2011, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 26,588 € and equity of 192,565 €; its revenue is not published. With 0.7 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 45.7%, above the median of its sector (37.8%).
Companies similar to B.K. Pharma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie Botanique Retail sale of pharmaceutical products Brussels · balance sheet 421,353 €
- Apotheek Ophasselt Retail sale of pharmaceutical products Geraardsbergen · balance sheet 422,127 €
- Benatpharma Retail sale of pharmaceutical products Jette · balance sheet 420,772 €
- Hestia Retail sale of pharmaceutical products Ghent · balance sheet 419,536 €
- Budin-Conserva Retail sale of pharmaceutical products Roeselare · balance sheet 419,437 €
- Frenaver Retail sale of pharmaceutical products Heist-op-den-Berg · balance sheet 418,862 €
- Coriphar Retail sale of pharmaceutical products Tienen · balance sheet 425,689 €
- Apotheke Bocken Retail sale of pharmaceutical products Eupen · balance sheet 426,403 €
Frequently asked questions about B.K. Pharma
What is the revenue of B.K. Pharma?
B.K. Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of B.K. Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0834173472 for B.K. Pharma, if the company is VAT-registered. Its company number (CBE) is 0834.173.472.
Where is the registered office of B.K. Pharma?
According to the CBE register, the registered office of B.K. Pharma is in 1070 Anderlecht.
What is the equity of B.K. Pharma?
At the close of the 2025 financial year, the equity of B.K. Pharma amounts to 192,565 €, a solvency of 45.7% of total assets.
How many people work at B.K. Pharma?
0.7 full-time equivalents on average according to the 2025 social balance sheet.
Who manages B.K. Pharma?
The register lists 2 active mandates at B.K. Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of B.K. Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →